Efficacy and safety of drugs for nonalcoholic steatohepatitis.

Non-alcoholic steatohepatitis (NASH) is an inflammatory subtype of nonalcoholic fatty liver disease (NAFLD) and is associated with disease progression, development of cirrhosis. Lifestyle interventions are still the predominant treatment of NASH. No drugs for NASH treatment have been approved by FDA. Guidelines recommend that vitamin E might be used conditionally for NASH patients without type 2 diabets mellitus(T2D) and combination of pioglitazone and vitamin E is ideal to NASH patients with T2D. Encouragingly, the development of NASH drugs is emerging for different mechanisms. Some drugs are under the phase III clinical stage, including: obeticholic acid (OCA), elafibranor, cenicriviroc, selonsertib, resmetirom, Emricasan and Aramchol. Especially, due to the interim positive effect for the improvement of liver fibrosis, OCA has been filling to FDA and is waiting for the final approval for the treatment of NASH. Therefore, it is urgent to review the efficacy and safety of drugs for NASH in current clinical trials. This article is protected by copyright. All rights reserved.